Vav 2 Oncogene (VAV2)

[Edit]

Guanine Nucleotide Exchange Factor VAV2

Vav 2 Oncogene (VAV2)
VAV2 is the second member of the VAV oncogene family. Unlike VAV1, which is expressed exclusively in hematopoietic cells, VAV2 transcripts were found in most tissues.Its overall exon organization is similar to that of VAV1. Alternative splicing of exons 6, 16, and 28 generates at least 2 distinct VAV2 mRNA species.
Moores et al. (2000) expressed VAV1, VAV2, and VAV3 at equivalent levels and found that each responds to similar surface receptor tyrosine kinases. Integrin-induced phosphorylation required the presence of SYK . Only VAV1 could efficiently cooperate with T-cell receptor (TCR) signaling to enhance NFAT-dependent transcription, while only VAV1 and VAV3 could enhance nuclear factor kappa-B (NFKB)-dependent transcription.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPE928Hu01 Recombinant Vav 2 Oncogene (VAV2) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies n/a Monoclonal Antibody to Vav 2 Oncogene (VAV2) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Vav 2 Oncogene (VAV2) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Vav 2 Oncogene (VAV2) CLIA Kit Customized Service Offer
n/a ELISA Kit for Vav 2 Oncogene (VAV2) ELISA Kit Customized Service Offer

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Vav 2 Oncogene (VAV2) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Vav 2 Oncogene (VAV2) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Vav 2 Oncogene (VAV2) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Vav 2 Oncogene (VAV2) CLIA Kit Customized Service Offer
n/a ELISA Kit for Vav 2 Oncogene (VAV2) ELISA Kit Customized Service Offer

Organism species: Rattus norvegicus (Rat)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Vav 2 Oncogene (VAV2) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Vav 2 Oncogene (VAV2) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Vav 2 Oncogene (VAV2) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Vav 2 Oncogene (VAV2) CLIA Kit Customized Service Offer
n/a ELISA Kit for Vav 2 Oncogene (VAV2) ELISA Kit Customized Service Offer
  1. "Identification of VAV2 on 9q34 and its exclusion as the tuberous sclerosis gene TSC1."Ann. Hum. Genet. 59:25-37(1995) [PubMed] [Europe PMC] [Abstract]
  2. "DNA sequence and analysis of human chromosome 9." Nature 429:369-374(2004) [PubMed] [Europe PMC] [Abstract]
  3. "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)."Genome Res. 14:2121-2127(2004) [PubMed] [Europe PMC] [Abstract]
  4. "The full-ORF clone resource of the German cDNA consortium."BMC Genomics 8:399-399(2007) [PubMed] [Europe PMC] [Abstract]
  5. "Mechanism of epidermal growth factor regulation of Vav2, a guanine nucleotide exchange factor for Rac."J. Biol. Chem. 278:5163-5171(2003) [PubMed] [Europe PMC] [Abstract]
  6. "The proto-oncogene Fgr regulates cell migration and this requires its plasma membrane localization."Exp. Cell Res. 302:253-269(2005) [PubMed] [Europe PMC] [Abstract]
  7. "Novel association of Vav2 and Nek3 modulates signaling through the human prolactin receptor."Mol. Endocrinol. 19:939-949(2005) [PubMed] [Europe PMC] [Abstract]
  8. "A probability-based approach for high-throughput protein phosphorylation analysis and site localization."Nat. Biotechnol. 24:1285-1292(2006) [PubMed] [Europe PMC] [Abstract]
  9. "Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle."Mol. Cell 31:438-448(2008) [PubMed] [Europe PMC] [Abstract]
  10. "A quantitative atlas of mitotic phosphorylation."Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008) [PubMed] [Europe PMC] [Abstract]
  11. "Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach."Anal. Chem. 81:4493-4501(2009) [PubMed] [Europe PMC] [Abstract]
  12. "Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis."Sci. Signal. 3:RA3-RA3(2010) [PubMed] [Europe PMC] [Abstract]
  13. "Initial characterization of the human central proteome."BMC Syst. Biol. 5:17-17(2011) [PubMed] [Europe PMC] [Abstract]
  14. "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome."J. Proteomics 96:253-262(2014) [PubMed] [Europe PMC] [Abstract]
  15. "Solution structure of the SH2 domain and of the second SH3 domain of human protein VAV-2."Submitted (APR-2007) to the PDB data bank